Peggy Sotiropoulou
Chief Scientific Officer T-Knife Therapeutics
Dr. Peggy Sotiropoulou is Chief Scientific Officer and Director at T-knife Therapeutics, where she leads the development of supercharged T-cell therapies for solid tumors. She brings more than 20 years of experience in immuno-oncology and cell therapy, advancing programs from discovery to clinic. Before joining T-knife, she was Head of R&D at Celyad Oncology, where she led the development of autologous and allogeneic CAR-T platforms. She previously served as a tenured Research Associate Professor at Université Libre de Bruxelles, focused on tumor response and sensitization to therapy. Dr. Sotiropoulou holds a Ph.D. in Cancer Immunotherapy from the University of Crete and a B.S. in Biology from the University of Athens.
Seminars
- Reviewing how emerging clinical data is shaping market perspectives on in vivo cell therapies to guide smart pipeline decisions
- Examining the resurgence of next-generation in vivo CAR-Ts and ex vivo explorations for solid tumours and autoimmune disease to identify where each modality can unlock the greatest opportunity
- Aligning scientific, manufacturing, regulatory and commercial perspectives on the future direction of the field to accelerate clinical impact
- Applying key learnings from ex vivo developments to optimise indication selection, targeting strategies, and clinical translation for in vivo approaches
- Discussing the key scientific, regulatory considerations to streamline the integration of in vivo cell therapies into the pipeline
- Exploring the specific challenges raised by solid tumours to in vivo cell therapy
- Designing approaches to all tackle key challenges
- Preclinical data demonstrating in vivo therapies for solid tumours
